Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abelacimab in High-risk Patients With Atrial Fibrillation Unsuitable for Oral Anticoagulation
NCT05712200Phase 3Recruiting
- Sponsor
- Anthos Therapeutics
- Start
- Dec 2022
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 35
01
Overview
A Phase 3 trial of abelacimab in Atrial fibrillation (AFib), sponsored by Anthos Therapeutics. Started Dec 2022; status: recruiting.
02
Drugs
abelacimab
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05712200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712200.